MX2024001099A - Medicamento para el tratamiento y/o prevencion de cancer. - Google Patents
Medicamento para el tratamiento y/o prevencion de cancer.Info
- Publication number
- MX2024001099A MX2024001099A MX2024001099A MX2024001099A MX2024001099A MX 2024001099 A MX2024001099 A MX 2024001099A MX 2024001099 A MX2024001099 A MX 2024001099A MX 2024001099 A MX2024001099 A MX 2024001099A MX 2024001099 A MX2024001099 A MX 2024001099A
- Authority
- MX
- Mexico
- Prior art keywords
- medicament
- cancer
- prevention
- treatment
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021122071 | 2021-07-27 | ||
| PCT/JP2022/028877 WO2023008461A1 (ja) | 2021-07-27 | 2022-07-27 | 癌の治療及び／又は予防のための医薬品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001099A true MX2024001099A (es) | 2024-02-23 |
Family
ID=85087718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001099A MX2024001099A (es) | 2021-07-27 | 2022-07-27 | Medicamento para el tratamiento y/o prevencion de cancer. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250325663A1 (https=) |
| EP (1) | EP4378477A4 (https=) |
| JP (1) | JPWO2023008461A1 (https=) |
| KR (1) | KR20240042415A (https=) |
| CN (1) | CN117651566A (https=) |
| AU (1) | AU2022316644A1 (https=) |
| CA (1) | CA3227703A1 (https=) |
| MX (1) | MX2024001099A (https=) |
| WO (1) | WO2023008461A1 (https=) |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| DK1069185T3 (da) | 1998-04-03 | 2011-06-27 | Chugai Pharmaceutical Co Ltd | Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| DE10359795A1 (de) | 2003-12-19 | 2005-07-21 | Bayer Technology Services Gmbh | Strangverdampfervorrichtung |
| BRPI0911926A2 (pt) | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
| EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
| EP2480671B8 (en) | 2009-09-22 | 2015-10-28 | ProBioGen AG | Process for producing molecules containing specialized glycan structures |
| HUE040012T2 (hu) | 2010-02-04 | 2019-02-28 | Toray Industries | Gyógyászati ágens rák kezelésére és/vagy megelõzésére |
| DK2532366T3 (da) | 2010-02-04 | 2017-01-02 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
| DK2532680T3 (da) | 2010-02-04 | 2015-07-20 | Toray Industries | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer |
| CA2788545C (en) | 2010-02-04 | 2019-03-26 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| US9115200B2 (en) | 2010-02-04 | 2015-08-25 | Toray Industries, Inc. | Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1 |
| RU2603742C2 (ru) | 2010-02-04 | 2016-11-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| JP2013528357A (ja) | 2010-03-29 | 2013-07-11 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| PL2740793T3 (pl) | 2011-08-04 | 2018-04-30 | Toray Industries, Inc. | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PT2740489T (pt) | 2011-08-04 | 2017-01-10 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático |
| PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| EP2740794B1 (en) | 2011-08-04 | 2018-04-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| WO2013125654A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| ES2739612T3 (es) * | 2012-02-21 | 2020-02-03 | Toray Industries | Composición farmacéutica para el tratamiento de cáncer |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| WO2013147176A1 (ja) | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 胆嚢癌の治療及び／又は予防用医薬組成物 |
| JP6107654B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| AU2014303375B2 (en) | 2013-08-09 | 2019-07-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| CN107408520B (zh) | 2015-03-03 | 2022-02-25 | 卢茨·瑞布斯道克 | 检查系统 |
| AU2019242520B2 (en) * | 2018-03-30 | 2026-02-26 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| CA3175137A1 (en) * | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
-
2022
- 2022-07-27 WO PCT/JP2022/028877 patent/WO2023008461A1/ja not_active Ceased
- 2022-07-27 CN CN202280050655.2A patent/CN117651566A/zh active Pending
- 2022-07-27 AU AU2022316644A patent/AU2022316644A1/en active Pending
- 2022-07-27 MX MX2024001099A patent/MX2024001099A/es unknown
- 2022-07-27 EP EP22849522.2A patent/EP4378477A4/en active Pending
- 2022-07-27 CA CA3227703A patent/CA3227703A1/en active Pending
- 2022-07-27 JP JP2022554213A patent/JPWO2023008461A1/ja active Pending
- 2022-07-27 KR KR1020247002781A patent/KR20240042415A/ko active Pending
- 2022-07-27 US US18/292,656 patent/US20250325663A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023008461A1 (ja) | 2023-02-02 |
| US20250325663A1 (en) | 2025-10-23 |
| CN117651566A (zh) | 2024-03-05 |
| KR20240042415A (ko) | 2024-04-02 |
| AU2022316644A1 (en) | 2024-02-29 |
| EP4378477A4 (en) | 2025-08-13 |
| EP4378477A1 (en) | 2024-06-05 |
| CA3227703A1 (en) | 2023-02-02 |
| JPWO2023008461A1 (https=) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021044208A8 (en) | Antibody-drug conjugate comprising antibody against human ror1, and use for the same | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
| WO2021239935A9 (en) | Neutralizing antibodies against sars-related coronavirus | |
| RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2012137505A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| AU2011332810A8 (en) | Anti-IL-6 antibodies for the treatment of oral mucositis | |
| MX2021005823A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo. | |
| MX2022008471A (es) | Anticuerpo anti-angptl3 y uso del mismo. | |
| MY209791A (en) | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| WO2019089753A3 (en) | Cd137 antibodies and pd-1 antagonists and uses thereof | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| EA201100884A1 (ru) | Моноклональные антитела анти-rhd | |
| MX2023015149A (es) | Conjugados de fármacos peptídicos. | |
| ZA202309150B (en) | Antibody against nkp46 and application of antibody | |
| MX2025001452A (es) | Anticuerpos anti-ccr8 y metodos de uso | |
| MX2025012052A (es) | Molecula de union a antigeno que se une especificamente a egfr y muc1, conjugado farmaceutico del mismo y uso medico del mismo | |
| MX2026000793A (es) | Anticuerpo muc1 humanizado y conjugado anticuerpo-farmaco | |
| MX2024001099A (es) | Medicamento para el tratamiento y/o prevencion de cancer. |